Skip to main content
. 2014 Oct 20;33(1):42–50. doi: 10.1200/JCO.2014.56.8253

Fig 2.

Fig 2.

Kaplan-Meier survival curves of interaction of BRAF V600E mutation with clinicopathologic risk factors in affecting disease-free probability in patients with papillary thyroid cancer (all types). (A) Lymph node metastasis (LNM) and BRAF V600E mutation, (B) tumor extrathyroidal extension (EXT) and BRAF V600E mutation, and (C) patients age ≥ 60 years and BRAF V600E mutation. In each panel, P values were from log-rank tests, adjusted for multiple comparisons, comparing each stratum with patients negative for both BRAF V600E mutation and indicated clinicopathologic factor. Follow-up time truncated at 15 years.